NCT06610734 2026-02-09
SKY
Sichuan University
Phase 2 Recruiting
Clinical Trials
14 trialsNCT05856695 2025-09-24
TAXIO
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Active not recruiting
NCT06982287 2025-07-08
A Retrospective Real-World Study on the Efficacy and Safety of Anlotinib Hydrochloride Combined With Immunotherapy Maintenance Therapy Following Standard Chemoimmunotherapy for ES-SCLC (ALTER-L059)
Sir Run Run Shaw Hospital
Not yet recruiting
NCT07022301 2025-06-15
Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy
First Affiliated Hospital of Wannan Medical College
Phase 2 Not yet recruiting
NCT06429696 2025-05-28
PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer
Nanfang Hospital, Southern Medical University
Phase 2 Recruiting
NCT06348797 2025-05-16
Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
Sichuan University
Phase 1 Recruiting
NCT06851819 2025-02-28
TERE
Hebei Medical University Fourth Hospital
Phase 2 Not yet recruiting
NCT06825208 2025-02-13
Etoposide Plus Benmelstobart Followed by Maintenance Therapy of Benmelstobart Plus Anlotinib in First-line Treatment of Elderly Patients with Extensive Stage Small Cell Lung Cancer: a Single-arm, Prospective Trial
Nanjing First Hospital, Nanjing Medical University
Not yet recruiting
NCT05745350 2025-02-11
First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Recruiting
NCT04462276 2025-01-30
TREASURE
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT06739928 2024-12-18
Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC
Guangzhou Institute of Respiratory Disease
Phase 2 Recruiting
NCT05066945 2021-10-04
Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients
Xiangya Hospital of Central South University
Not yet recruiting
NCT04967625 2021-07-28
A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT02179528 2014-09-12
Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC)
Peking University Cancer Hospital & Institute
Phase 2 Unknown